Histology-based classification predicts pattern of recurrence and improves risk stratification in primary retroperitoneal sarcoma

Annals of Surgery

Volumn 263, Issue 3, 2016, Pages 593-600

  Tan, Marcus C B ^a,b   Brennan, Murray F ^a   Kuk, Deborah ^a   Agaram, Narasimhan P ^a   Antonescu, Cristina R ^a   Qin, Li Xuan ^a   Moraco, Nicole ^a   Crago, Aimee M ^a   Singer, Samuel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Histology; leiomyosarcoma; liposarcoma; retroperitoneum; sarcoma; solitary fibrous tumor; tumor recurrence

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVOR; CONFERENCE PAPER; DATA BASE; DEDIFFERENTIATED LIPOSARCOMA; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; EXCISION; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; LAPAROTOMY; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MYXOSARCOMA; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; RETROPERITONEAL SARCOMA; RISK ASSESSMENT; SOLITARY FIBROUS TUMOR; WELL DIFFERENTIATED LIPOSARCOMA; AGE; INCIDENCE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RETROPERITONEAL NEOPLASMS; SARCOMA; SURVIVAL RATE; TUMOR RECURRENCE; TUMOR VOLUME;

AGE FACTORS; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; RETROPERITONEAL NEOPLASMS; RISK ASSESSMENT; SARCOMA; SURVIVAL RATE; TUMOR BURDEN;

EID: 84959284555     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001149     Document Type: Conference Paper

References (37)

1. Singer S, Maki RG, O'Sullivan B. Soft tissue sarcoma. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2011:1533-1576.
2. Thomas DM, O'Sullivan B, Gronchi A. Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management. Expert Rev Anticancer Ther. 2009;9:1145-1157.
3. Lewis JJ, Leung D, Woodruff JM, et al. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998;228:355-365.
4. Dalal KM, Kattan MW, Antonescu CR, et al. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006;244:381-391.
5. Singer S, Antonescu CR, Riedel E, et al. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003;238:358-370; discussion 370-371.
6. Bonvalot S, Rivoire M, Castaing M, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol. 2009;27:31-37.
7. Brown RE, St Hill CR, Greene QJ, et al. Impact of histology on survival in retroperitoneal sarcomas. Am J Surg. 2011;202:748-752; discussion 752-753.
8. Gronchi A, Miceli R, Shurell E, et al. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J Clin Oncol. 2013;31:1649-1655.
9. Nathan H, Raut CP, Thornton K, et al. Predictors of survival after resection of retroperitoneal sarcoma: a population-based analysis and critical appraisal of the AJCC staging system. Ann Surg. 2009;250:970-976.
10. Fletcher CDM, Bridge JA, Hogendoorn P, et al. WHO Classification of Tumours of Soft Tissue and Bone. In: WHO Classification of Tumours. Lyon, France: IARC Press; 2013.
11. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assn. 1999;94:496-509.
12. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
13. Wolbers M, Koller MT,Witteman JC, et al. Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology. 2009;20:555-561.
14. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002;20:791-796.
15. Edge SB, Byrd DR, Compton CC, et al. The AJCC Cancer Staging Manual. New York, NY: Springer; 2010.
16. Gronchi A. Extended surgery for retroperitoneal sarcoma: the key to maximizing the potential for cure and survival. Pro Oncology (Williston Park). 2013;27:640-642.
17. Gronchi A, Lo Vullo S, Fiore M, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol. 2009;27:24-30.
18. Gronchi A, Miceli R, Colombo C, et al. Frontline extended surgery is associated with improved survival in retroperitoneal low-to intermediategrade soft tissue sarcomas. Ann Oncol. 2012;23:1067-1073.
19. Mussi C, Colombo P, Bertuzzi A, et al. Retroperitoneal sarcoma: is it time to change the surgical policy? Ann Surg Oncol. 2011;18:2136-2142.
20. Gronchi A, Pollock R. Surgery in retroperitoneal soft tissue sarcoma: a call for a consensus between Europe and North America. Ann Surg Oncol. 2011;18: 2107-2110.
21. Gronchi A, Pollock RE. Quality of local treatment or biology of the tumor: which are the trump cards for loco-regional control of retroperitoneal sarcoma? Ann Surg Oncol. 2013;20:2111-2113.
22. Pollock RE. Extended surgery for retroperitoneal sarcoma: too much surgery for some and not enough for others? Con Oncology (Williston Park). 2013;27: 641-642.
23. Raut CP, Swallow CJ. Are radical compartmental resections for retroperitoneal sarcomas justified? Ann Surg Oncol. 2010;17:1481-1484.
24. Bonvalot S, Miceli R, Berselli M, et al. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. Ann Surg Oncol. 2010;17: 1507-1514.
25. Kattan MW, Heller G, Brennan MF. A competing-risks nomogram for sarcoma-specific death following local recurrence. Stat Med. 2003;22: 3515-3525.
26. Anaya DA, Lahat G, Wang X, et al. Postoperative nomogram for survival of patients with retroperitoneal sarcoma treated with curative intent. Ann Oncol. 2010;21:397-402.
27. Abbott AM, Habermann EB, Parsons HM, et al. Prognosis for primary retroperitoneal sarcoma survivors: a conditional survival analysis. Cancer. 2012;118:3321-3329.
28. Maki RG, Moraco N, Antonescu CR, et al. Toward better soft tissue sarcoma staging: building on American Joint Committee on Cancer Staging Systems versions 6 and 7. Ann Surg Oncol. 2013;20:3377-3383.
29. Eilber FC, Brennan MF, Eilber FR, et al. Validation of the postoperative nomogram for 12-year sarcoma-specific mortality. Cancer. 2004;101:2270-2275.
30. Mariani L, Miceli R, Kattan MW, et al. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer. 2005;103:402-408.
31. Singer S, Socci ND, Ambrosini G, et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res. 2007;67:6626-6636.
32. Coindre JM,Mariani O, Chibon F, et al. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol. 2003;16:256-262.
33. Bremjit PJ, Jones RL, Chai X, et al. A contemporary large single-institution evaluation of resected retroperitoneal sarcoma. Ann Surg Oncol. 2014;21: 2150-2158.
34. Heslin MJ, Lewis JJ, Woodruff JM, et al. Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surg Oncol. 1997;4:425-431.
35. Gobble RM, Qin LX, Brill ER, et al. Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. Cancer Res. 2011;71:2697-2705.
36. Crago AM, Socci ND, DeCarolis P, et al. Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability. Clin Cancer Res. 2012;18:1334-1340.
37. Taylor BS, DeCarolis PL, Angeles CV, et al. Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. Cancer Discov. 2011;1:587-597.